XML 39 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 9 Months Ended
Jun. 18, 2021
USD ($)
Oct. 07, 2020
USD ($)
Oct. 03, 2018
USD ($)
Target
Sep. 28, 2016
USD ($)
Jul. 31, 2021
USD ($)
Jan. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
May 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jul. 31, 2020
USD ($)
Organization And Significant Accounting Policies [Line Items]                      
Cash received as due under agreement           $ 300,000,000.0          
Proceeds from the issuance of common stock               $ 250,479,000      
Cash and cash equivalents             $ 325,981,000     $ 143,583,000  
Restricted Cash             2,400,000        
Short-term investments             63,924,000     86,890,000  
Marketable securities             126,400,000        
Long-term investments             128,376,000     $ 137,487,000  
Net increase (decrease) in cash and investments             $ 191,700,000        
ASU No. 2018-18                      
Organization And Significant Accounting Policies [Line Items]                      
Change in accounting principle, accounting standards update, adopted [true false]             true        
Change in accounting principle, accounting standards update, adoption date             Oct. 01, 2020        
Change in accounting principle, accounting standards update, immaterial effect [true false]             true        
ASU No. 2018-15                      
Organization And Significant Accounting Policies [Line Items]                      
Change in accounting principle, accounting standards update, adopted [true false]             true        
Change in accounting principle, accounting standards update, adoption date             Oct. 01, 2020        
Change in accounting principle, accounting standards update, immaterial effect [true false]             true        
Takeda License Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Cash received as due under agreement           $ 300,000,000.0          
Profit sharing structure ratio   50.00%                  
Development regulatory and commercial milestones payments   $ 740,000,000.0                  
Takeda License Agreement | Maximum                      
Organization And Significant Accounting Policies [Line Items]                      
Tiered royalties received percentage   25.00%                  
Takeda License Agreement | Minimum                      
Organization And Significant Accounting Policies [Line Items]                      
Tiered royalties received percentage   20.00%                  
Janssen                      
Organization And Significant Accounting Policies [Line Items]                      
Milestone payment     $ 60,000,000.0                
Milestone payments                 $ 10,000,000    
Janssen | ARO-JNJ1                      
Organization And Significant Accounting Policies [Line Items]                      
Milestone payment                 $ 10,000,000    
Janssen | License Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Agreement date     Oct. 03, 2018                
Janssen | License Agreement | Maximum                      
Organization And Significant Accounting Policies [Line Items]                      
Development regulatory and sales milestones payments     $ 1,600,000,000                
Janssen | Collaboration Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Number of additional targets for development and sales milestone payments | Target     3                
Janssen | Collaboration Agreement | Maximum                      
Organization And Significant Accounting Policies [Line Items]                      
Development regulatory and sales milestones payments     $ 1,900,000,000                
Janssen and JJDC | Collaboration and License agreements                      
Organization And Significant Accounting Policies [Line Items]                      
Cash received as due under agreement     175,000,000.0                
JJDC | Common Stock Purchase Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Proceeds from the issuance of common stock     $ 75,000,000.0                
Agreement date     Oct. 03, 2018                
Amgen Incorporated | Collaboration and License agreements                      
Organization And Significant Accounting Policies [Line Items]                      
Agreement date       Sep. 28, 2016              
Amgen Incorporated | Olpasiran Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Milestone payment                     $ 20,000,000.0
Milestone payments       $ 30,000,000.0              
Amgen Incorporated | Olpasiran Agreement | Maximum                      
Organization And Significant Accounting Policies [Line Items]                      
Development regulatory and sales milestones payments             $ 400,000,000.0        
Amgen Incorporated | License Collaboration and Stock Purchase Agreement                      
Organization And Significant Accounting Policies [Line Items]                      
Cash received as due under agreement       35,000,000.0              
Proceeds from the issuance of common stock       $ 21,500,000              
Horizon Therapeutics Ireland DAC | Collaboration and License agreements                      
Organization And Significant Accounting Policies [Line Items]                      
Development regulatory and commercial milestones payments $ 660,000,000                    
Agreement date Jun. 18, 2021                    
Horizon Therapeutics Ireland DAC | Collaboration and License agreements | Subsequent Event                      
Organization And Significant Accounting Policies [Line Items]                      
Cash received as due under agreement         $ 40,000,000